Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Case Presentations: How Therapeutic Advances in Glaucoma Could Improve Patient Care

By: Thomas W. Samuelson, MD; Janet B. Serle, MD

Webinar Credits: 1

Expiration Date: Thursday, March 05, 2020
Release Date: March 6, 2019



Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Discuss the chemical structure and mechanism of action of topical glaucoma medications and evolving neuroprotective medications.
  • Explain the anti-fibrotic activity in novel drug classes.
  • Evaluate novel therapeutics and classes of drugs and their potential for enhanced patient compliance.

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In cooperation with Evolve Medical Education LLC, the University of Houston College of Optometry has reviewed and endorsed this course.

Evolve is an approved COPE Administrator. This course is COPE approved for 1.0 hours of CE Credit for Optometrists.
COPE Course ID: 61669-GL
COPE Event ID: 117060

COPE EXPIRATION DATE: March 4, 2022

 

Faculty and Disclosures

Janet B. Serle, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:  Aerie Pharmaceuticals. Allergan, plc., and Bausch & Lomb. Grant/Research Support:  Allergan plc,  and Ocular Therapeutics. Stock Options: Aerie Pharmaceuticals.

Thomas Samuelson, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AcuMEMS; Aerie Pharmaceuticals; Akorn; Alcon Surgical; AMO (Abbott Medical Optics) AqueSys; Bausch and Lomb; BELKIN Laser; Endo Optics; Equinox; Glaukos Corporation; and Ivantis; Ocular Surgery News; PolyActiva, Santen Pharmaceutical Co, Ltd; Shire Plc; Transcend Medical, Veracity Innovations, LLC; and Vindico/Slack. Stock Options: Equinox; Glaukos Corporation; and Ivantis.

Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education, Susan Gallagher-Pecha, director of client services and project management, Evolve; and Michelle Dalton, writer have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

Off-Label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Aerie Pharmaceuticals.

Pretest

  • 1 Not at all confident2345 Extremely confident
  • 1 Not at all confident2345 Extremely confident

Video Resources

Next

Test

Instructions

Step 1 of 3

33%
  • AgreeNeutralDisagree
    Discuss the chemical structure and mechanism of action of topical glaucoma medications and evolving neuroprotective medications.
    Explain the anti-fibrotic activity in novel drug classes.
    Evaluate novel therapeutics and classes of drugs and their potential for enhanced patient compliance.
Back